Idexx Laboratories Inc /De (IDXX): who owns it and who trades it
As of Nov 16, 2026, IDXX insiders reported 53 open-market sales worth $58.4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jonathan Jay Mazelsky (CEO), with $33M. 9 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Idexx Laboratories
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IDXX
1,297 funds and institutions reported IDXX shares worth $39.4B at the end of Q2 2026, about 95% of the company. The largest holder is BlackRock, Inc. with 10.4%.
Funds and institutions (13F) 95%Everyone else 5%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 8.17M | 10.36% | $4.3B | -2% |
| Vanguard Capital Management LLC | 5.15M | 6.53% | $2.7B | -1% |
| Vanguard Portfolio Management LLC | 3.90M | 4.94% | $2.1B | -0% |
| State Street Corp | 3.75M | 4.75% | $2B | +2% |
| Invesco Ltd. | 3.61M | 4.58% | $1.9B | +115% |
| Geode Capital Management, LLC | 2.56M | 3.25% | $1.3B | -4% |
| Bamco Inc | 1.98M | 2.51% | $1B | +21% |
| Morgan Stanley | 1.36M | 1.72% | $714M | +3% |
| Bank of New York Mellon Corp | 1.19M | 1.51% | $628M | -21% |
| Arrowstreet Capital, Limited Partnership | 1.07M | 1.35% | $562M | +27% |
| Fundsmith LLP | 1.02M | 1.29% | $537M | -30% |
| Blair William & Co | 918,556 | 1.16% | $484M | -3% |
| Northern Trust Corp | 918,137 | 1.16% | $483M | +1% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 911,489 | 1.16% | $480M | +5% |
| FMR LLC (Fidelity) | 822,643 | 1.04% | $433M | +191% |
| American Century Companies Inc | 808,358 | 1.02% | $426M | +35% |
| Capital Research Global Investors | 789,111 | 1.00% | $415M | +1% |
| JPMorgan Chase & Co | 755,791 | 0.96% | $405M | – |
| Principal Financial Group Inc | 743,246 | 0.94% | $391M | -16% |
| Goldman Sachs Group Inc | 738,708 | 0.94% | $389M | +3% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IDXX insiders reported $0 of open-market purchases and $58.4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Daniel M Junius | Director | Sale | 700 | $705.78 | $494K | Form 4 |
| Nov 4, 2026 | Daniel M Junius | Director | Sale | 500 | $701.68 | $351K | Form 4 |
| Nov 4, 2026 | Michael Lane | Vice president | Sale | 243 | $687.85 | $167K | Form 4 |
| Nov 4, 2026 | Michael Lane | Vice president | Sale | 2,059 | $689.70 | $1.4M | Form 4 |
| Nov 4, 2026 | Michael Lane | Vice president | Sale | 1,677 | $687.46 | $1.2M | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 1,945 | $698.26 | $1.4M | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 4,075 | $699.33 | $2.8M | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 1,667 | $700.33 | $1.2M | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 4,540 | $701.36 | $3.2M | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 2,136 | $702.21 | $1.5M | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 3,950 | $703.45 | $2.8M | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 240 | $705.59 | $169K | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 840 | $707.00 | $594K | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 1,840 | $707.84 | $1.3M | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 1,300 | $709.00 | $922K | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 1,501 | $710.12 | $1.1M | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 775 | $711.31 | $551K | Form 4 |
| Nov 4, 2026 | Jonathan Jay Mazelsky | Chair | Sale | 331 | $711.95 | $236K | Form 4 |
| Nov 4, 2026 | Sharon E. Underberg | Vice president | Sale | 6,348 | $688.25 | $4.4M | Form 4 |
| Nov 4, 2026 | Sharon E. Underberg | Vice president | Sale | 1,503 | $689.05 | $1M | Form 4 |
| Nov 4, 2026 | Sharon E. Underberg | Vice president | Sale | 1,055 | $690.02 | $728K | Form 4 |
| Sep 4, 2026 | Lawrence D Kingsley | Director | Sale | 2,203 | $532.08 | $1.2M | Form 4 |
| Mar 3, 2026 | Nimrata Hunt | Vice president | Sale | 1,758 | $634.57 | $1.1M | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 2,860 | $657.84 | $1.9M | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 1,095 | $651.49 | $713K | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 1,281 | $650.67 | $834K | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 2,589 | $663.04 | $1.7M | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 1,000 | $662.16 | $662K | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 1,200 | $661.10 | $793K | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 2,859 | $659.75 | $1.9M | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 1,669 | $652.49 | $1.1M | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 1,171 | $653.68 | $765K | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 1,111 | $654.63 | $727K | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 1,488 | $655.85 | $976K | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 1,343 | $656.85 | $882K | Form 4 |
| Feb 26, 2026 | Jonathan Jay Mazelsky | CEO | Sale | 3,660 | $658.92 | $2.4M | Form 4 |
| Feb 26, 2026 | Nimrata Hunt | Vice president | Sale | 2,693 | $661.54 | $1.8M | Form 4 |
| Feb 17, 2026 | Michael G Erickson | Vice president | Sale | 456 | $623.76 | $284K | Form 4 |
| Feb 17, 2026 | Michael G Erickson | Vice president | Sale | 204 | $625.24 | $128K | Form 4 |
| Feb 17, 2026 | Michael G Erickson | Vice president | Sale | 1,288 | $626.26 | $807K | Form 4 |
| Feb 17, 2026 | Michael G Erickson | Vice president | Sale | 2,694 | $628.22 | $1.7M | Form 4 |
| Feb 17, 2026 | Michael G Erickson | Vice president | Sale | 689 | $629.09 | $433K | Form 4 |
| Feb 17, 2026 | Michael G Erickson | Vice president | Sale | 40 | $629.86 | $25.2K | Form 4 |
| Feb 17, 2026 | Sophie V. Vandebroek | Director | Sale | 945 | $628.65 | $594K | Form 4 |
| Feb 17, 2026 | Sophie V. Vandebroek | Director | Sale | 519 | $628.56 | $326K | Form 4 |
| Feb 10, 2026 | George Fennell | Vice president | Sale | 1,130 | $643.00 | $727K | Form 4 |
| Feb 10, 2026 | George Fennell | Vice president | Sale | 397 | $644.02 | $256K | Form 4 |
| Feb 10, 2026 | George Fennell | Vice president | Sale | 2,161 | $645.25 | $1.4M | Form 4 |
| Feb 10, 2026 | George Fennell | Vice president | Sale | 1,060 | $647.21 | $686K | Form 4 |
| Feb 10, 2026 | George Fennell | Vice president | Sale | 966 | $648.78 | $627K | Form 4 |
| Feb 10, 2026 | George Fennell | Vice president | Sale | 2,809 | $649.26 | $1.8M | Form 4 |
| Feb 10, 2026 | George Fennell | Vice president | Sale | 40 | $650.32 | $26K | Form 4 |
| Feb 10, 2026 | George Fennell | Vice president | Sale | 2,782 | $646.23 | $1.8M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jonathan Jay Mazelsky | President and CEO, Director | – | $33M | Nov 4, 2026 |
| George Fennell | Executive Vice President | – | $7.3M | Feb 10, 2026 |
| Sharon E. Underberg | EVP, GC & Corporate Secretary | – | $6.1M | Nov 4, 2026 |
| Michael G Erickson | Executive Vice President | – | $3.4M | Feb 17, 2026 |
| Nimrata Hunt | Executive Vice President | – | $2.9M | Mar 3, 2026 |
| Michael Lane | Executive Vice President | – | $2.7M | Nov 4, 2026 |
| Lawrence D Kingsley | Director | – | $1.2M | Sep 4, 2026 |
| Sophie V. Vandebroek | Director | – | $920K | Feb 17, 2026 |
| Daniel M Junius | Director | – | $845K | Nov 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IDXX short interest
Low short interest. 3.0% of IDXX shares are sold short: about 1 share in 33. Over the last 12 reports the number of shares short went up 17%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.35M IDXX shares were sold short, 3.0% of the shares outstanding, up 22.0% from the report before. At the average daily volume of 529,434 shares, buying them all back would take about 4.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.35M | 2.99% | +22% | 529,434 | 4.5 |
| Oct 15, 2026 | 1.93M | 2.45% | -1% | 532,582 | 3.6 |
| Sep 30, 2026 | 1.94M | 2.46% | +1% | 496,267 | 3.9 |
| Sep 15, 2026 | 1.92M | 2.43% | -8% | 509,073 | 3.8 |
| Aug 31, 2026 | 2.09M | 2.66% | +8% | 481,225 | 4.3 |
| Aug 14, 2026 | 1.94M | 2.46% | +1% | 736,898 | 2.6 |
| Jul 31, 2026 | 1.93M | 2.45% | -8% | 486,815 | 4.0 |
| Jul 15, 2026 | 2.10M | 2.66% | +8% | 702,942 | 3.0 |
| Jun 30, 2026 | 1.94M | 2.46% | -9% | 770,218 | 2.5 |
| Jun 15, 2026 | 2.14M | 2.71% | -2% | 569,513 | 3.8 |
| May 29, 2026 | 2.18M | 2.76% | +8% | 649,587 | 3.4 |
| May 15, 2026 | 2.02M | 2.56% | -3% | 667,433 | 3.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded IDXX
Since Nov 17, 2024, 4 members of Congress reported 11 purchases and 6 sales of IDXX. The latest was a sale by April McClain Delaney on Jan 13, 2026, reported Feb 2, 2026.
Purchases 11Sales 6
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Jan 13, 2026 | April McClain Delaney (D-MD) | Sale | $1K–$15K | Child | Feb 2, 2026 | Report |
| Oct 16, 2025 | April McClain Delaney (D-MD) | Partial sale | $1K–$15K | Child | Nov 4, 2025 | Report |
| Sep 4, 2025 | Byron Donalds (R-FL) | Purchase | $1K–$15K | Self | Oct 7, 2025 | Report |
| Sep 4, 2025 | Byron Donalds (R-FL) | Purchase | $1K–$15K | Spouse | Oct 7, 2025 | Report |
| Aug 7, 2025 | April McClain Delaney (D-MD) | Partial sale | $1K–$15K | Child | Sep 2, 2025 | Report |
| Jul 9, 2025 | April McClain Delaney (D-MD) | Partial sale | $1K–$15K | Child | Aug 5, 2025 | Report |
| May 15, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $1K–$15K | Self | Jun 9, 2025 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $100K–$250K | Self | Jun 22, 2025 | Report |
| Apr 9, 2025 | April McClain Delaney (D-MD) | Purchase | $1K–$15K | Child | May 2, 2025 | Report |
| Apr 8, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Self | Apr 28, 2025 | Report |
| Apr 7, 2025 | Jefferson Shreve (R-IN) | Purchase | $50K–$100K | Self | May 8, 2025 | Report |
| Apr 7, 2025 | April McClain Delaney (D-MD) | Purchase | $1K–$15K | Child | May 2, 2025 | Report |
| Apr 4, 2025 | April McClain Delaney (D-MD) | Purchase | $1K–$15K | Child | May 2, 2025 | Report |
| Apr 1, 2025 | April McClain Delaney (D-MD) | Purchase | $1K–$15K | Child | May 2, 2025 | Report |
| Mar 14, 2025 | April McClain Delaney (D-MD) | Purchase | $1K–$15K | Child | Apr 2, 2025 | Report |
| Mar 13, 2025 | Jefferson Shreve (R-IN) | Purchase | $15K–$50K | Self | Apr 11, 2025 | Report |
| Feb 25, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Purchase | $1K–$15K | Self | Mar 27, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Idexx Laboratories company events
Idexx Laboratories filed 8 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026ResultsReleased financial results. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- May 15, 2026VoteReported shareholder vote results. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Mar 26, 2026LeadershipIDEXX Laboratories, Inc. and Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, mutually agreed that Dr. Hunt will cease serving in her current role effective on April 13, 2026 and will continue to provide advisory services on an as-needed basis until July 13, 2026. Filing
- Feb 13, 2026LeadershipMs. M. Anne Szostak provided IDEXX Laboratories, Inc. notice of her intention to retire from the Board of Directors effective immediately following the Company’s 2026 Annual Meeting of Stockholders to be held on May 12, 2026. Filing
- Feb 2, 2026ResultsReleased financial results. Filing
- Jan 13, 2026LeadershipReported a change among its top officers or directors, or their pay. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Idexx Laboratories financials
Famous investors that hold IDXX
9 of the 50 well-known investors we track reported holding IDXX in their latest 13F filing. The largest position is Terry Smith's, worth $373M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Terry Smith · Fundsmith | Q3 2026 | 714,883 | $373M | 2.9% | -30% |
| Israel Englander · Millennium Management | Q3 2026 | 306,290 | $160M | 0.1% | +288% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 173,958 | $90.8M | 0.2% | -34% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 109,644 | $57.3M | 0.1% | -0% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 101,626 | $53.1M | 0.0% | +162% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 38,921 | $20.3M | 0.1% | +16% |
| Larry Robbins · Glenview Capital Management | Q3 2026 | 1,200 | $627K | 0.0% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 521 | $272K | 0.0% | New |
| Bill Nygren · Harris Associates (Oakmark) | Q3 2026 | 455 | $238K | 0.0% | No change |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named IDXX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 30, 2026 | Vanguard Portfolio Management | 13G | 5.0% |
| Oct 30, 2026 | Vanguard Portfolio Management | 13G | 5.0% |
Questions about Idexx Laboratories Inc /De (IDXX) stock
Who owns the most IDXX stock?
The largest reported owner of Idexx Laboratories Inc /De (IDXX) is BlackRock, Inc., with 10.4% of the company. In total, 1,297 funds and institutions reported holding IDXX at the end of Q2 2026, together about 95% of the shares. See the largest owners.
Are IDXX insiders buying or selling?
In the last 12 months, IDXX insiders reported no open-market purchases and 53 sales worth $58.4M. The latest trade was on Nov 4, 2026. See every trade.
What is the short interest in IDXX?
As of Oct 30, 2026, 2.35M IDXX shares were sold short, 3.0% of the shares outstanding, up 22.0% from the report before. At the average daily volume of 529,434 shares, buying them all back would take about 4.5 trading days (days to cover). See the history.
Have members of Congress traded IDXX?
Yes. 4 members of Congress reported 11 purchases and 6 sales of IDXX since Nov 17, 2024. The latest was reported on Feb 2, 2026. See the trades.
Which famous investors hold IDXX?
9 of the 50 well-known investors we track reported IDXX in their latest 13F filing, including Terry Smith, Israel Englander, Steve Cohen. The largest position is worth $373M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.